PTJ
IONS icon

Paul Tudor Jones’s Ionis Pharmaceuticals IONS Stock Holding History

Paul Tudor Jones’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270K Buy
+3,400
New +$256K ﹤0.01% 3185
2025
Q2 		– Sell
-12,800
Closed -$386K – 3486
2025
Q1 		$386K Buy
12,800
+2,500
+24% +$81.9K ﹤0.01% 2446
2024
Q4 		$360K Buy
+10,300
New +$385K ﹤0.01% 2462

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Paul Tudor Jones's IONS Position: Q2 2026 in Review

Paul Tudor Jones sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 48,244 shares — an estimated $3.63M sold.

Paul Tudor Jones first reported a position in IONS in Q4 2014 and held it in 22 quarters. The position peaked at $6.76M in Q3 2021. 510 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Paul Tudor Jones reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 48,244 Ionis Pharmaceuticals shares in Q2 2026, an estimated $3.63M.
  • Paul Tudor Jones first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 22 quarters.
  • Paul Tudor Jones's Ionis Pharmaceuticals position peaked at $6.76M in Q3 2021.
  • 510 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.